Compare CarMax, Inc (KMX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Sana Biotechnology Inc — how do they compare? CarMax, Inc trades at $57.7 (market cap $8.18B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: CarMax, Inc is far larger — about 9.3× Sana Biotechnology Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| KMX | SANA | |
|---|---|---|
Market Cap | $8.18B | $879.40M |
Sector | Consumer Cyclical | Health |
52-Week High | $63.53 | $5.92 |
52-Week Low | $30.88 | $2.68 |
Enterprise Value | $26.69B | $853.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $57.61, up 0.49% on the day, with a bullish technical outlook supported by moving averages and a strong ADX signal. Recent Q1 2026 earnings beat expectations, driven by cost control and revenue growth, though net income margins remain thin at 0.84%. The company's four-pillar strategy focuses on volume, digital sales, and efficiency, with positive analyst coverage highlighting value and momentum potential.
The stock's upside is supported by operational improvements and insider buying, but risks include high debt levels, margin pressure, and a pending legal investigation. Analyst consensus is cautious with a $48.91 price target below the current price, suggesting limited near-term upside amid execution risks.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
